TKNONasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Alpha Teknova, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$6.80−0.28 (-3.95%)
Close on Oct 19, 2026
- Market cap
- $364.72M
- P/E (TTM)
- –
- Dividend yield
- –
Alpha Teknova, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lab Essentials [Member] | $9.18M | $8.40M | $6.83M | $8.31M | $7.79M | $8.12M | $6.82M | $7.16M | $7.64M | $7.27M | $6.69M | $7.27M | 75.4% | +17.9% |
| Clinical Solutions [Member] | $2.43M | $2.15M | $2.72M | $1.71M | $2.06M | $1.16M | $1.85M | $1.96M | $1.57M | $1.72M | $879.00K | $597.00K | 19.9% | +17.9% |
| Other [Member] | $573.00K | $537.00K | $435.00K | $440.00K | $435.00K | $516.00K | $597.00K | $451.00K | $411.00K | $306.00K | $300.00K | $298.00K | 4.7% | +31.7% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $11.66M | $10.56M | $9.37M | $9.83M | $9.78M | $9.27M | $8.76M | $9.06M | $9.23M | $8.87M | $7.37M | $7.83M | 95.7% | +19.2% |
| International [Member] | $526.00K | $516.00K | $616.00K | $622.00K | $510.00K | $523.00K | $501.00K | $519.00K | $386.00K | $420.00K | $495.00K | $342.00K | 4.3% | +3.1% |
From the segment and revenue-disaggregation notes of Alpha Teknova's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.